Replies to post #51028 on Genta, Inc (fka GNTAQ)

[fmrick]

Survival in a Phase 3, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH) (AGENDA). Abstract #8531. Poster Session: Monday, June 6, 2011 8:00 AM-12:30 PM; Discussion Session 11:30 AM-12:30 PM.

this is the day !

Dude, I hope you are not pinning your hopes to that trial.

That is the FAILED Agenda trial.